Form 4: Director Mohit Kaushal Sells TOI Shares

Director Mohit Kaushal sold 95,719 shares of The Oncology Institute, Inc. (TOI) via a pre-arranged Rule 10b5-1 trading plan.

Summary

• Director Mohit Kaushal executed the sale of 95,719 shares of common stock in The Oncology Institute, Inc.
• The sales occurred in two tranches on April 14, 2026, and April 16, 2026.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on December 16, 2025.
• Following these transactions, the director retains beneficial ownership of 172,583 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were conducted under a pre-planned 10b5-1 arrangement, which is a standard mechanism for insider liquidity.

Positives

• The sales were executed under a pre-established Rule 10b5-1 plan, which typically indicates the sales were planned in advance for liquidity or diversification purposes rather than based on non-public information.

Negatives

• The sale of shares by a company director can sometimes be perceived by the market as a lack of confidence in the short-term stock performance.

Risks

• Continued selling by insiders may exert downward pressure on the stock price.
• Market perception of insider selling could negatively impact investor sentiment.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a standard practice for corporate executives and directors to manage personal liquidity, and it is generally viewed as less significant than open-market sales made outside of such plans.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is a standard governance practice for directors at publicly traded healthcare companies to avoid potential conflicts with insider trading regulations.

Stakeholder Impact

• Shareholders should note the reduction in the director's equity stake, though the pre-planned nature of the sale mitigates concerns regarding insider sentiment.

Next Steps

• Monitor future Form 4 filings for any additional insider activity.

Key Dates

Keywords

TOI, The Oncology Institute, Insider Trading, Form 4, Mohit Kaushal, Rule 10b5-1